Compare CEPU & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CEPU | WGS |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | Argentina | United States |
| Employees | N/A | 1300 |
| Industry | Electric Utilities: Central | Retail: Computer Software & Peripheral Equipment |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2017 | N/A |
| Metric | CEPU | WGS |
|---|---|---|
| Price | $15.09 | $76.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $17.50 | ★ $140.71 |
| AVG Volume (30 Days) | 288.0K | ★ 722.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.76 | $29.98 |
| Revenue Next Year | $28.12 | $24.85 |
| P/E Ratio | ★ $12.24 | $1,251.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.43 | $55.17 |
| 52 Week High | $18.50 | $170.87 |
| Indicator | CEPU | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 39.35 |
| Support Level | $14.88 | $68.55 |
| Resistance Level | $16.60 | $95.94 |
| Average True Range (ATR) | 0.65 | 5.58 |
| MACD | 0.03 | 0.82 |
| Stochastic Oscillator | 45.52 | 31.38 |
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.